It is now the first and only Tdap vaccine in the US approved for a repeat dose in people 10 through 64 years of age eight years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.
The FDA licensure was based on clinical data from a study of the safety and effectiveness of repeat Adacel vaccination in adults.
In the study of more than 1,300 adults (aged 18 through 64 years), participants received either Adacel vaccine or a tetanus-diphtheria vaccine 8-12 years after a previous dose of Adacel vaccine.
The results of the study published in the Journal of the Pediatric Infectious Diseases Society showed a second dose of Adacel vaccine in adults administered 8-12 years after a previous dose found no significant differences in adverse events between vaccine groups.
A total of 87.7% of Tdap vaccine recipients (n=999) and 88.0% of Td vaccine recipients (n=328) reported at least 1 injection-site reaction.
Sanofi Pasteur has provided the results of the study to the CDC's Advisory Committee on Immunization Practices for their consideration in future recommendations.
The US Centers for Disease Control and Prevention currently recommends a single dose of Tdap vaccine for adolescents and adults, and for pregnant women during every pregnancy.
Tdap helps protect adolescents and adults and may prevent the spread of the infection to babies and young children who are still building immunity.5 Despite the CDC-recommendation, nearly three of four adults have not received the Tdap vaccine.
Adacel vaccine is given to people 10 through 64 years of age to help prevent tetanus (lockjaw), diphtheria, and pertussis (whooping cough).
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Merck KGaA to acquire JSR Life Sciences chromatography business to expand Protein A capabilities
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
INOVIO announces inducement grant to new employee
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
LakeShore Biopharma receives Nasdaq delisting determination letter
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
INOVIO to release Q2 2025 financial results on 12 August
Bavarian Nordic chikungunya vaccine enters Health Canada review process
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy